Page 1

PAVmed PAVmed Provides Business Update and Preliminary Second Quarter 2021 Financial Results August 12 , 2021 Conference call to be held today at 4:30 PM EDT NEW YORK -- ( BUSINESS WIRE ) -- PAVmed Inc. ( Nasdaq : PAVM , PAVMZ ) ( the " Company " or " PAVmed " ) , a highly differentiated , multi - product , commercial - stage medical device company , today provided a business update for the Company and its major subsidiary , Lucid Diagnostics Inc. ( " Lucid " ) , and discussed preliminary financial results for the three and six months ended June 30 , 2021 . " I am pleased to report on the solid momentum we have experienced during the second quarter of 2021 and in subsequent weeks , " said Lishan Aklog , M.D. , PAVmed's Chairman and Chief Executive Officer . " In late 2020 , we decided to embark on a bigger and bolder strategic plan for PAVmed and its subsidiaries to fully realize their long - term potential for success . We decided to accelerate our plans to grow the company on multiple fronts including expanding and expediting our EsoGuard commercialization plans , laying the groundwork to take Lucid public , more aggressively seeking out attractive partnerships , licensing , and M & A opportunities , bringing fresh perspectives , experiences , skill sets and diversity to our two Boards , critically evaluate and assess ways to future - proof our relationship with a couple of mission - critical partners , and to do all this while strengthening our balance sheet and growing shareholder value . Nine months later , I am very pleased this strategic plan is bearing fruit and enhancing shareholder value . " Conference Call and Webcast A conference call and webcast for today's business update and second quarter 2021 financial results will take place at 4:30 PM EDT . To access the conference call , listeners should dial ( 877 ) 407-3982 toll - free in the U.S. or ( 201 ) 493-6780 , and ask to join the " PAVmed , Inc. Business Update Conference Call " . The conference call will be available live via webcast and for replay at the investor relations section of the Company's website at www.pavmed.com . Following the conclusion of the conference call , a replay will be available for one week and can be accessed by dialing ( 844 ) 512-2921 toll - free in the U.S. or ( 412 ) 317-6671 , followed by the PIN number : 13720826 . Business Update Highlights Lucid began testing patients referred by primary care physicians ( " PCPs " ) at three Lucid Test Centers in the Phoenix metropolitan area . Patients with chronic heartburn , also known as gastroesophageal reflux disease ( " GERD " ) , who are referred to the centers are now undergoing an esophageal precancer procedure , performed by Lucid employed clinical personnel , using Lucid's EsoCheck® Cell Collection Device ( " EsoCheck " ) to collect surface esophageal cells for its EsoGuard® Esophageal Test